Treatment with rilonacept, canakinumab or anakinra, compounds that act to suppress IL‐1β have greatly improved the life expectancy of CAPS patients, indicating that uncontrolled inflammation is damaging. Here, IL1B is linked to cryopyrin-associated periodic syndrome.